Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.
This is written in the approval document as:
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | ER positive | Invasive Breast Carcinoma | Anastrozole | |
| HSE (1) | PR positive | Invasive Breast Carcinoma | Anastrozole | |
| HSE (1) | ER positive, PR positive | Invasive Breast Carcinoma | Anastrozole |